# Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

> **NCT01563445** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 40 (actual)

## Conditions studied

- Acquired Bleeding Disorder
- Intracerebral Haemorrhage

## Interventions

- **DRUG:** activated recombinant human factor VII
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01563445
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01563445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01563445, "Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01563445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*